News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
651,419 Results
Type
Article (52602)
Company Profile (354)
Press Release (598463)
Section
Business (187870)
Career Advice (2687)
Deals (34287)
Drug Delivery (97)
Drug Development (81576)
Employer Resources (165)
FDA (16436)
Job Trends (15433)
News (328886)
Policy (32991)
Tag
Academia (2857)
Africa (931)
Alliances (47826)
Alzheimer's disease (1207)
Antibody-drug conjugate (ADC) (60)
Approvals (16362)
Arizona (132)
Artificial intelligence (72)
Asia (38710)
Australia (6649)
Bankruptcy (336)
Best Places to Work (11464)
Biosimilars (69)
Biotechnology (269)
C2C Services and Suppliers (69270)
California (1678)
Canada (790)
Cancer (380)
Career advice (2258)
Cell therapy (119)
China (122)
Clinical research (63563)
Collaboration (126)
Colorado (70)
COVID-19 (2718)
Cystic fibrosis (77)
Data (169)
Diabetes (77)
Diagnostics (6057)
Drug pricing (75)
Earnings (69536)
Employer resources (145)
Europe (88308)
Events (94236)
Executive appointments (116)
FDA (16624)
Florida (219)
Funding (112)
Gene therapy (93)
GLP-1 (585)
Government (4614)
Healthcare (19156)
Hotbed/Location (436477)
Illinois (251)
Indiana (139)
Infectious disease (2745)
Inflammatory bowel disease (97)
Interviews (502)
IPO (15374)
Job creations (4062)
Job search strategy (1904)
Kansas (94)
Layoffs (451)
Legal (7483)
Liver cancer (60)
Lung cancer (84)
Manufacturing (83)
Maryland (366)
Massachusetts (1303)
Medical device (13044)
Medtech (13047)
Mergers & acquisitions (18741)
Metabolic disorders (262)
Michigan (114)
Minnesota (204)
Neuroscience (1350)
New Jersey (472)
New York (501)
NextGen Class of 2024 (6945)
Non-profit (4846)
North Carolina (618)
Northern California (742)
Obesity (160)
Ohio (94)
Opinion (212)
Patents (67)
Pennsylvania (482)
People (54919)
Phase I (19742)
Phase II (27854)
Phase III (21150)
Pipeline (101)
Policy (58)
Postmarket research (2593)
Preclinical (8169)
Press Release (64)
Rare diseases (125)
Real estate (5800)
Recruiting (68)
Regulatory (21855)
Research institute (2523)
Resumes & cover letters (412)
South America (1291)
Southern California (669)
Startups (3674)
Texas (186)
United States (7599)
Vaccines (538)
Washington State (234)
Weight loss (150)
Date
Today (6)
Last 7 days (561)
Last 30 days (2004)
Last 365 days (37210)
2024 (24982)
2023 (39835)
2022 (50961)
2021 (55401)
2020 (54485)
2019 (47842)
2018 (36504)
2017 (33372)
2016 (32590)
2015 (37253)
2014 (29255)
2013 (24020)
2012 (25671)
2011 (26348)
2010 (23955)
651,419 Results for "oncoarendi therapeutics sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
RELIEF THERAPEUTICS Holding SA announces the results of its annual general meeting (AGM) of shareholders, which took place in Geneva today.
June 27, 2024
·
3 min read
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA announces the results of the extraordinary general meeting of shareholders, which took place in Geneva , Friday, April 26, 2024.
April 26, 2024
·
4 min read
Business
ExcellGene SA and Cytovance Biologics Join Forces to Transform Large Molecule Biologics Development and Manufacture
ExcellGene SA proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization based in the USA.
May 8, 2024
·
3 min read
Deals
Stryker completes acquisition of SERF SAS
Stryker (NYSE: SYK), a leading global medical technology company, announced today that it has completed the previously announced acquisition of SERF SAS, a France -based joint replacement company, from Menix.
March 21, 2024
·
4 min read
Drug Development
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
OSE Immunotherapeutics SA, presented a poster on preclinical data on its mRNA therapeutic platform for the treatment of inflammatory and autoimmune disorders at the Federation of Clinical Immunology Societies annual meeting held in San Francisco.
June 20, 2024
·
8 min read
Press Releases
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools
August 1, 2024
·
3 min read
Drug Development
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154 , the world’s first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine.
February 5, 2024
·
8 min read
Business
Relief Therapeutics Announces Executive Changes - June 4, 2024
RELIEF THERAPEUTICS Holding SA today announced that interim Chief Executive Officer Michelle Lock has completed her transitional mandate with the Company.
June 3, 2024
·
2 min read
Business
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world’s first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine.
February 5, 2024
·
7 min read
Inhalis Therapeutics SA Achieves Key Milestone with Patent Application Filing
Inhalis Therapeutics SA, a pioneering privately-held company specializing in advanced inhaled treatments for life-threatening diseases, proudly reveals a significant stride forward as it submits a new patent application on INHAL-101, its lead asset.
August 21, 2023
·
2 min read
1 of 65,142
Next